99.25 USD
+1.35 (+1.38%)
99.25 USD
0 (0%)
Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 185 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD has a decent growth rate and is not valued too expensively. With these ratings, IRMD could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
IRMD had a positive operating cash flow in the past year.
IRMD had positive earnings in each of the past 5 years.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
IRMD has a Return On Assets of 18.47%. This is amongst the best in the industry. IRMD outperforms 98.92% of its industry peers.
Looking at the Return On Equity, with a value of 21.54%, IRMD belongs to the top of the industry, outperforming 94.59% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 19.30%, IRMD belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.84%.
The last Return On Invested Capital (19.30%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.31%, IRMD belongs to the top of the industry, outperforming 95.68% of the companies in the same industry.
IRMD's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 30.87%, IRMD belongs to the top of the industry, outperforming 98.38% of the companies in the same industry.
In the last couple of years the Operating Margin of IRMD has grown nicely.
IRMD has a better Gross Margin (77.07%) than 89.19% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
The number of shares outstanding for IRMD has been increased compared to 5 years ago.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IRMD has an Altman-Z score of 48.62. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
IRMD's Altman-Z score of 48.62 is amongst the best of the industry. IRMD outperforms 99.46% of its industry peers.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 48.62 |
ROIC/WACC1.94
WACC9.95%
2.3 Liquidity
A Current Ratio of 6.64 indicates that IRMD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 6.64, IRMD belongs to the best of the industry, outperforming 84.32% of the companies in the same industry.
A Quick Ratio of 5.72 indicates that IRMD has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.72, IRMD belongs to the best of the industry, outperforming 85.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.75%, which is quite good.
Measured over the past years, IRMD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.92% on average per year.
The Revenue has grown by 12.91% in the past year. This is quite good.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
3.2 Future
IRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.26% yearly.
The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y15.29%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year13.26%
Revenue Next 2Y11.69%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 54.53 indicates a quite expensive valuation of IRMD.
IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.19% of the companies in the same industry.
IRMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
IRMD is valuated quite expensively with a Price/Forward Earnings ratio of 45.90.
Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than the industry average as 70.27% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, IRMD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.53 | ||
| Fwd PE | 45.9 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 67.03% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 70.27% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 90.5 | ||
| EV/EBITDA | 46.02 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.57
PEG (5Y)3.92
EPS Next 2Y14.48%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
With a yearly dividend of 0.68%, IRMD is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.19, IRMD pays a better dividend. On top of this IRMD pays more dividend than 91.35% of the companies listed in the same industry.
With a Dividend Yield of 0.68, IRMD pays less dividend than the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.59% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.59%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
99.25
+1.35 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners57.86%
Inst Owner Change0.47%
Ins Owners36.79%
Ins Owner Change-0.63%
Market Cap1.26B
Revenue(TTM)80.51M
Net Income(TTM)21.18M
Analysts82.5
Price Target100.98 (1.74%)
Short Float %3.85%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)0%
PT rev (3m)34.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.04%
EPS NY rev (1m)0%
EPS NY rev (3m)0.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.53 | ||
| Fwd PE | 45.9 | ||
| P/S | 15.68 | ||
| P/FCF | 90.5 | ||
| P/OCF | 50.48 | ||
| P/B | 12.84 | ||
| P/tB | 13.29 | ||
| EV/EBITDA | 46.02 |
EPS(TTM)1.82
EY1.83%
EPS(NY)2.16
Fwd EY2.18%
FCF(TTM)1.1
FCFY1.1%
OCF(TTM)1.97
OCFY1.98%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)3.57
PEG (5Y)3.92
Graham Number17.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROCE | 24.38% | ||
| ROIC | 19.3% | ||
| ROICexc | 43.34% | ||
| ROICexgc | 46.82% | ||
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% | ||
| FCFM | 17.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1128.47% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.82% | ||
| Profit Quality | 65.85% | ||
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 | ||
| Altman-Z | 48.62 |
F-Score4
WACC9.95%
ROIC/WACC1.94
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y15.29%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
Revenue Next Year13.26%
Revenue Next 2Y11.69%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.31%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y98.66%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
Can you provide the valuation status for IRADIMED CORP?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IRADIMED CORP (IRMD) stock?
The Price/Earnings (PE) ratio for IRADIMED CORP (IRMD) is 54.53 and the Price/Book (PB) ratio is 12.84.
Can you provide the financial health for IRMD stock?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.